Send to

Choose Destination
Rev Esp Salud Publica. 2016 Apr 13;90:E15.

[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

Servicio de Dermatología. Hospital Universitario Puerta de Hierro.
Departamento de Economía Aplicada. Universidad Autónoma de Madrid. España.
Departamento de Análisis Económico I. Universidad Nacional de Educación a Distancia. España.
Departamento de Administración de Servicios de Enfermería. Universidad Nacional de Educación a Distancia. España.


in English, Spanish


The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies.


We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75.Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs.


The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1).


when taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.


Adalimumab; Cost-Effectiveness Analysis; Economic Evaluation; Infliximab; Methotrexate; Psoriasis; Spain; Ustekinumab

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Revista Espanola de Salud Publica
Loading ...
Support Center